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Background: Previous studies have demonstrated the utility and sensitivity of the CogState Brief Battery (CBB) in
detecting cognitive impairment in Alzheimer’s disease (AD) and mild cognitive impairment (MCI) and in assessing
cognitive changes in the preclinical stages of AD. Thus, the CBB may be a useful screening tool to assist in the
management of cognitive function in clinical settings. In this study, we aimed to determine the utility of the CBB in
identifying the nature and magnitude of cognitive impairments in MCI and AD.
Methods: Healthy adults (n = 653) adults with amnestic MCI (n = 107), and adults with AD (n = 44) who completed
the CBB participated in this study. Composite Psychomotor/Attention and Learning/Working Memory scores were
computed from the individual CBB tests. Differences in composite scores were then examined between the three
groups; and sensitivity and specificity analyses were conducted to determine cut scores for the composite scores
that were optimal in identifying MCI- and AD-related cognitive impairment.
Results: Large magnitude impairments in MCI (g = 2.2) and AD (g = 3.3) were identified for the learning/working
memory composite, and smaller impairments were observed for the attention/psychomotor composite (g’s = 0.5
and 1, respectively). The cut-score associated with optimal sensitivity and specificity in identifying MCI-related
cognitive impairment on the learning/working memory composite was -1SD, and in the AD group, this optimal
value was −1.7SD. Both composite scores showed high test-retest reliability (r = 0.95) over four months. Poorer
performance on the memory composite was also associated with worse performance on the Mini Mental State
Exam and increasing severity on the Clinical Dementia Rating Scale sum of boxes score.
Conclusions: Results of this study suggest that the CogState learning/working memory composite score is reduced
significantly in CI and AD, correlate well with measures of disease classification and are useful in identifying
memory impairment related to MCI- and AD.Background
The importance of screening for dementia in individuals
at risk of neurodegenerative diseases is now widely ac-
cepted (Snyder 2013). While advances in neuroimaging
and fluid biomarkers show much promise for identifying
early Alzheimer’s disease (AD), neuropsychological test-
ing remains the cornerstone of early disease recognition
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reproduction in any medium, provided the ormost neuropsychological test batteries shown to be
sensitive to early AD require substantial time and ex-
pertise for both administration and scoring and this can
limit their potential for use in wide-scale screening
(Fredrickson et al. 2010). While some brief bedside cog-
nitive screening instruments (i.e. measures that require
less than 30 minutes for administration) such as the
Mini Mental State Examination (MMSE) (Folstein et al.
1975) and Montreal Cognitive Assessment (MoCA)
(Nasreddine et al. 2005) have been shown to be useful in
case finding studies of AD and MCI, their relative lack
of sensitivity to detecting subtle cognitive impairment
has been well documented (McKhann et al. 2011;Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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syncratic errors in administration (Miller et al. 2008;
Miller et al. 2011). Furthermore, although items on these
bedside screening instruments are selected to assess a
wide variety of cognitive domains, subscale scores on
these instruments generally have low validity and reli-
ability (Strauss et al. 2006).
The CogState Brief Battery (CBB) is a brief, computer-
administered cognitive test battery that requires approxi-
mately 10 minutes for administration and consists of
four cognitive tasks that measure psychomotor function,
attention, working memory and memory (Darby et al.
2012; Fredrickson et al. 2010; Maruff et al. 2009). The
sensitivity of the CBB to detect cognitive impairment in
several neurodegenerative conditions has been demon-
strated in prior work (Darby et al. 2009; Hammers et al.
2012; Lim et al. 2012a). Given that the CBB is computer-
ized, the administration, scoring and reporting is auto-
mated and highly standardized. Each task in the battery
is constructed using playing cards as stimuli with the
test taker required to answer only “yes” or “no” on each
trial in accord with a simple rule. The simple stimuli,
rules and responses have been combined to generate
cognitive paradigms that have been well-validated in
neuropsychological and cognitive studies. These include
measures of psychomotor function (Detection task), vis-
ual attention (Identification task), working memory
(One Back task) and visual learning set within a pattern
separation model (One Card Learning task, (Fredrickson
et al. 2010; Maruff et al. 2009)). The simplicity of the
CBB has allowed it to be applied successfully to the meas-
urement of cognitive function in healthy older adults and
in adults with clinically diagnosed and prodromal AD
(Darby et al. 2009; Lim et al. 2012a, b). These studies have
found that performance on the CBB working memory and
learning tasks are sensitive to cognitive impairment in
clinically diagnosed AD as well as its prodromal stage;
amnestic MCI. Furthermore, the CBB was designed spe-
cifically for repeated administration, as it can be adminis-
tered repeatedly without generating significant practice
effects (Collie et al. 2003; Falleti et al. 2006), including in
healthy older people (Fredrickson et al. 2010). The CBB
has been shown to be sensitive to AD-related cognitive
decline in healthy older adults and in adults with amnestic
MCI (Darby et al. 2002, 2012; Lim et al. 2013a, b) as well
as to improvement in cognition arising from treatment
with putative cognitive enhancing drugs such as donepezil
(Jaeger et al. 2011), histamine H3 antagonists (Nathan
et al. 2013) and testosterone (Davison et al. 2011) in
older people.
Recent data from studies using the CBB suggests that
composite scores, which are constructed from aggregat-
ing performance on the Detection and Identification
tasks (i.e., an attention/psychomotor composite) and thelearning and working memory tasks (i.e., a learning/
working memory composite) may have greater sensitivity
to both AD-related cognitive impairment and decline
when compared to scores from the individual CBB tasks
(Lim et al. in press, 2012b, c). This increased sensitivity
of cognitive composite scores over individual test scores
is consistent with current neuropsychological models
that emphasise the benefit of composite scores in clinical
research (Nuechterlein et al. 2008).
While the CBB is not intended to replace formal
neuropsychological assessment, the results of these re-
cent studies do converge to suggest that it may be useful
as a screening test for AD-related cognitive impairment
in clinical settings. However, the clinical utility of the
CBB in screening for AD-related cognitive impairment
has not been established formally. To achieve this, it is
necessary to compute estimates of sensitivity and specifi-
city of each composite score and identify their optimal
value for the identification of cognitive impairment related
to both AD and MCI. It is also necessary to understand
the nature of any relationship between each composite
measure and cognitive impairment across disease severity.
Finally, establishing the reliability and stability of these
composite scores would facilitate the use of composite
cognitive measures to monitor changes in cognitive func-
tion in clinical or prodromal AD.
The main aim of this study was to determine the sen-
sitivity, specificity and reliability of the CBB composite
scores for the detection and monitoring of cognitive im-
pairment in aging and dementia (Lim et al. 2012a, b).
The first hypothesis was that the attention/psychomotor
and learning/working memory composites would be sen-
sitive to AD-related cognitive impairment although the
sensitivity of the learning/working memory composite
would be greater than that of the attention/psychomotor
composite. We then examined the relationship between
each cognitive composite score and disease severity across
the clinical groups. Our second hypothesis was that on re-
assessment, both cognitive composite scores would show
high test-retest reliability and stability in healthy adults,
amnestic MCI and AD.
Methods
Participants
Participants in the current study were recruited from
the Australian Imaging, Biomarkers and Lifestyle (AIBL)
Study of Ageing (Ellis et al. 2009; Rowe et al. 2010) and
from hospital clinics specializing the diagnoses of AD
who had completed the CBB successfully as part of their
assessment (Lim et al. 2012a). The process of recruit-
ment and diagnostic classification been described in de-
tail previously for the AIBL (Ellis et al. 2009) and clinical
samples (Maruff et al. 2004). Of the AIBL participants
who had completed the CBB, 659 healthy adults (HA),
Table 1 Demographic and clinical characteristics for each
clinical group
HC (n = 659) MCI (n = 107) AD (n = 51)
Mean (SD) Mean (SD) Mean (SD)
Percentage females+ 57.8% 50.5% 51.0%
Age (years) 69.5 (6.6) 75.7 (7.5) 79.3 (7.2)
MMSE 28.7 (1.4) 26.1 (2.1) 19.8 (3.8)
CDR-SB 0.06 (0.3) 1.39 (1.2) 5.87 (2.4)
Premorbid IQ 108.35 (7.3) 105.9 (9.0) 103.2 (8.4)
Education level med 12 (9–15) 12 (9–15) 12 (9–15)
HADS depression 2.6 (2.2) 3.3 (2.4) 3.8 (3.1)
HADS anxiety 4.3 (2.9) 4.1 (2.6) 4.7 (3.7)
Detection speed* 100.0 (10.0) 94.26 (13.7) 91.72 (13.5)
Identification speed* 100.0 (10.0) 87.62 (16.4) 84.12 (15.4)
One card learning
accuracy*
100.0 (10.0) 83.74 (11.6) 78.42 (15.1)
One back accuracy* 100.0 (10.0) 79.18 (13.1) 70.14 (16.3)
Note: + = percentage of clinical group, med=median (range), * =mean score =100
and SD score = 10 because the mean and SD of the controls was used to
standardize the data for each individuals performance on each cognitive task. One
way ANOVAs indicated significant differences between groups on age, premorbid
IQ, and depressive symptoms, all p’s < 0.001. MMSE =Mini Mental State
Examination; CDR-SB = Clinical Dementia Rating Scale, Sum of Boxes Score;
HADS = Hospital Anxiety and Depression Scale.
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51 adults who met clinical criteria for mild to moderate
AD (Ellis et al. 2009) were recruited into the study. For
the hospital clinical sample 35 patients who met clinical
criteria for amnestic MCI were recruited (Maruff et al.
2004). Briefly, all patients underwent a detailed diagnos-
tic workup by clinician specializing in AD on the basis
of clinical, neuropsychological and structural neuroimag-
ing data. All cases of amnestic MCI were classified using
established criteria (Petersen et al. 1999; Winblad et al.
2004). All cases of AD met NINCDS-ADRDA criteria
for AD (McKhann et al. 1984). To increase the reliability
of classification, all individuals classified with MCI and
AD were required to meet the criteria for these clinical
classifications on two consecutive assessments. Data
from the CBB was not used by clinicians to classify any
individual’s clinical status. For participants with AD,
additional inclusion criteria included a score of 18 to 26
on the MMSE (Folstein et al. 1975). The severity of de-
mentia was rated in patients with AD and MCI using
the Clinical Dementia Rating (CDR) scale to provide a
sum of boxes score and an overall CDR score (Morris
1983). For all participants, exclusion criteria for the
study included: schizophrenia; depression (15-item Geri-
atric Depression Score (GDS) of 6 or greater); Parkin-
son’s disease; cancer (except basal cell skin carcinoma)
within the last two years; symptomatic stroke; uncon-
trolled diabetes; or current regular alcohol use exceeding
two standard drinks per day for women or four per day
for men. None of the control or MCI group were taking
psychotropic drugs or cholinesterase inhibitors although
each of the patients with AD were taking cholinesterase
inhibitors. Demographic and clinical characteristics of
the HC, MCI and AD groups are shown in Table 1. The
study complied with the regulations of three institutional
research and ethics committees (Ellis et al. 2009), and all
participants gave written informed consent prior to par-
ticipation in the study. To assess test-retest reliability,
we re-assessed 115 HA, 47 adults with MCI, and 43
adults with AD who underwent serial assessments on
the computerized cognitive battery. These individuals
were assessed monthly over four months (Lim et al.
2013b). The process of recruitment and additional inclu-
sion and exclusion criteria for this subgroup of AIBL
participants has been described in detail previously (Lim
et al. 2013b).
Measures
Demographic and clinical characteristics
Participants underwent a series of comprehensive demo-
graphic, health and cognitive tests performed by trained
research assistants under the supervision of licensed
clinical neuropsychologists. Participants’ age was based
on self-report, and this information was corroborated bya family member. Additionally, the MMSE, CDR,
Wechsler Test of Adult Reading (WTAR) (Wechsler
2001) and the Hospital Anxiety and Depression Scale
(HADS) (Snaith & Zigmond 1986) were administered to
participants to measure overall cognitive impairment,
general clinical function, premorbid IQ, and level of anx-
iety and depressive symptoms, respectively.
CogState brief battery
The four tasks from the CBB have been described in de-
tail previously (Darby et al. 2012; Lim et al. 2012a, b),
and they are summarized here. On each trial of each
task, a single playing card stimulus was presented in the
centre of the computer screen. The values, color and
suit of the playing cards were determined by the require-
ments of each task. At the presentation of each playing
card stimulus, participants were required to respond ei-
ther “yes” or “no” by pressing a “yes” or “no” button at-
tached to the computer through a USB port. The yes
button was always placed on the right and pressed with
the right hand and the no button was placed on the left
and pressed with the left hand. Patients were instructed
to press the “yes” or “no” button as quickly and as accur-
ately as possible. At the beginning of each task, task
rules were presented on the computer screen, and also
given verbally to the participant by the supervisor. This
was followed by an interactive demonstration in which
participants practiced the task. Once the practice trials
were complete, the task began. The four tasks were
Maruff et al. BMC Pharmacology and Toxicology 2013, 1:30 Page 4 of 11
http://www.biomedcentral.com/2050-7283/1/30presented in the same order. For each task, the speed
and accuracy of each response to each trial was recorded
and expressed as a mean reaction time (in milliseconds)
and accuracy (proportion correct). For each task a single
performance measure has been selected on the basis that
it comes from a normal data distribution, has no floor
or ceiling effects, does not have restricted range and
has good reliability, stability and sensitivity to change
(Fredrickson et al. 2010; Hammers et al. 2011). The
tasks from the CBB are described in their order of ad-
ministration below.
The Detection (DET) task is a simple reaction time
test shown to measure psychomotor function. In this
task, the participant must attend to the card in the cen-
ter of the screen and respond to the question “has the
card turned over?” Participants were instructed to press
the “Yes” button as soon as the card turns face up. The
face of the card is always the same generic joker card.
The task ends after 35 correct trials have been recorded.
Trials on which anticipatory responses occurred were
excluded and another trial was given so that all partici-
pants completed the 35 trials. The primary performance
measure for this task was reaction time in milliseconds
(speed), which was normalized using a logarithmic base
10 (log10) transformation.
The Identification (IDN) task is a choice reaction time
test shown to measure visual attention. In this task, the
participant must attend to the card in the center of the
screen, and respond to the question “Is the card red?”
Participants were required to press the “Yes” button if it
is and the “No” button it is not. The face of the cards
displayed were either red or black joker cards in equiva-
lent numbers in random order. These cards were differ-
ent to the generic joker card used in the DET task. The
task ends after 30 correct trials. Trials on which antici-
patory responses occurred were excluded and another
trial was given so that all participants completed the 30
trials. The primary performance measure for this task
was reaction time in milliseconds (speed), which was
normalized using a log10 transformation.
The One Card Learning (OCL) task is a continuous vis-
ual recognition learning task that assesses visual learning
within a pattern separation model (Yassa et al. 2010). The-
oretical models of pattern separation model specify that
information is organized in orthogonal and distinct non-
overlapping representations so that that new memories
can be stored rapidly without interference (Norman &
O'Reilly 2003). In this task the participant must attend to
the card in the center of the screen and respond to the
question “have you seen this card before in this task?” If
the answer was yes, participants were instructed to press
the “Yes” button, and the “No” button if the answer was
no. Normal playing cards were displayed (without joker
cards). In this task, six cards are drawn at random fromthe deck and are repeated throughout the task. These four
cards are interspersed with distractors (non-repeating
cards). The task ends after 80 trials, without rescheduling
for post-anticipatory correct trials. The primary perform-
ance measure for this task was the proportion of correct
answers (accuracy), which was normalized using an arc-
sine square-root transformation.
The One-Back (OBK) task is a task of working mem-
ory and attention. Similar in presentation to the OCL
task, participants must attend to the card in the center
of the screen and respond to the question “is this card
the same as that on the immediately previous trial?” If
the answer was yes, participants were instructed to press
the “Yes” button, and the “No” button if the answer was
no. The task ends after 30 correct trials. A correct but
post-anticipatory response led to scheduling of an extra
trial. The primary performance measure for this task was
the proportion of correct answers (accuracy), which was
normalized using an arcsine square-root transformation.
Data analysis
For each participant, each performance measure from
the four tasks in the CBB was computed as reported
previously (Lim et al. 2012a). For each performance
measure, the mean and standard deviation (SD) was
computed for the HA group according to their age in
deciles (e.g., 51–60, 61–70, 71–80, 81–90). These means
and SDs were then used to standardize scores on each of
the four cognitive tasks for each participant. A learning/
working memory composite score was computed by
averaging the standardized scores for the OCL and OBK
tasks, and an attention/psychomotor function composite
score was computed by averaging the standardized
scores for the DET and IDN tasks. For each individual,
both composite scores were then re-standardized using
the mean and SD for each composite score computed
from the HC group and then transformed once more so
that each had a mean of 100 and a standard deviation of
10. This was achieved by first multiplying each standard-
ized score by 10 and then adding 100. If data for one or
both of the tasks that contributed to each composite was
missing, the composite score was not computed. There
was no missing data for the attention/psychomotor func-
tion composite and 26 (HA = 17 cases, AD = 9 cases)
missing data for the learning/working memory compos-
ite score.
To evaluate the first hypothesis that the composite
scores would be sensitive to AD-related cognitive im-
pairment, we conducted two analysis of covariance
(ANCOVA), with age, premorbid IQ, and level of
depressive symptoms entered as covariates. For each
composite score, Hedge’s g was used to quantify the
magnitude of impairment in each of the clinical groups
relative to the healthy controls. We also determined the
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worse in the AD group than in the MCI using ANCOVA
with age, premorbid IQ, and level of depressive symp-
toms entered as covariates. Once again for each com-
parison Hedge’s g was used to quantify the magnitude of
impairment in the AD group relative to the MCI group.
Receiver operating characteristic (ROC) curves were
then generated to illustrate the relationship between
clinical sensitivity and specificity of each composite for
classification of MCI and AD groups, as measured by
the area under the curve (AUC) statistic. AUC values
were compared to those obtained for the MMSE in the
same analyses with statistical significance indicated
when 95% confidence intervals for each estimate did not
overlap. For classification of cognitive impairment in
MCI and AD, the value of each composite score that
provided the optimal balance between sensitivity and
specificity was identified from the ROC curve using
Youden’s J statistic (Swets 1996). The predictive power
of the combination of the optimum cut-score for each
composite in predicting MCI and AD was then deter-
mined by computing the odds ratios for the classifica-
tion of cognitive impairment in each clinical group
(versus the HC group). Finally the relationship between
the cognitive composite scores and disease severity was
determined by collapsing data for the MCI and AD
group and classifying each individual according to their
score on the CDR Sum of Boxes score. Curve fitting
analysis was then used to determine the extent to which
scores on each of the cognitive composites was associ-
ated with increased CDR Sum of Boxes scores.
To evaluate our second hypothesis that the cognitive
composite scores would show high test-retest reliability
and stability, we computed mean change scores and
test-retest reliability statistics over four months for the
two CogState composite scores. This was conducted in a
subgroup of AIBL participants who had consented to ser-
ial computerized cognitive assessments (Lim et al. 2013b).
Average measure intraclass correlation coefficients (ICC)
were used to compute the test-retest reliability of the two
composites, in both the total group and in each clinical
classification group separately.
Results
Cognitive function in healthy controls
In the HA group, the attention/psychomotor composite
was not associated significantly with premorbid IQ
(r = 0.07, p >0.05) or level of education. It was associated
significantly with levels of depressive (r = 0.11, p < 0.05)
and anxiety symptoms (r = 0.10, p < 0.05). The learning/
working memory composite was not associated signifi-
cantly with premorbid IQ (r = −0.06, p > 0.05), or levels
of depressive (r = 0.02, p > 0.05), or anxiety symptoms
(r = 0.01, p > 0.05).Magnitude of cognitive impairment in MCI and AD
As has been reported previously (Lim et al. 2012a), com-
parison of the demographic variables between clinical
groups indicated significant differences in age, premor-
bid IQ, and level of depressive symptoms (see Table 1).
As such, these variables were included as covariates in
comparisons of the CBB composite measures between
groups.
Results of the ANCOVAs revealed statistically signifi-
cant group differences for the learning/working memory
composite, F(2,769) = 305.56, p < 0.001, and the atten-
tion/psychomotor function composite, F(2,794) = 26.52,
p < 0.001. Post-hoc comparisons indicated that adults
with MCI and AD performed significantly worse than
HC on the learning/working memory composite, and
the magnitudes of these differences were, by convention,
large (MCI g = 2.15, 95% CI = 1.91, 2.38; AD g = 3.18,
95% CI = 2.91, 3.28). The AD group also performed sig-
nificantly worse than the MCI group on the learning/
working memory score with this difference moderate in
magnitude (g = 0.84 95% CI = 0.49, 1.18; p < 0.01). Adults
with MCI and AD also performed significantly worse
than HA on the attention/psychomotor composite, al-
though these differences were moderate-to-large in mag-
nitude (MCI g = 0.51, 95% CI = 0.30, 0.72; AD g = 1.03,
95% CI = 0.73, 1.33). The AD group also performed sig-
nificantly worse than the MCI group on the attention/
psychomotor function score with the differences moder-
ate in magnitude (is g = 0.40 95% CI = 0.07, 0.74).
Sensitivity and specificity of CBB composite scores in
assessing cognitive impairment in MCI and AD
Inspection of the AUC statistics from the ROC analyses
indicated that, by convention, the ROC curves for the
learning/working memory composite showed excellent
classification accuracy in both MCI and AD ((Swets
1996); Table 2; Figure 1). Accuracy of classification of
both MCI and AD was lower for the attention/psycho-
motor composite (see Table 2, Figure 1). AUC values for
the learning/working memory composite were signifi-
cantly larger (i.e. no overlap between 95% CIs for AUC
values) than for those for the attention/psychomotor
composite and for classifying cognitive impairment in
both MCI and AD (Table 2). Using the same criteria, the
AUC for the learning/working memory composite was
also significantly greater than the AUC for MMSE for
classifying cognitive impairment in MCI (Table 2). In-
spection of the Youden J statistics for the ROC curve for
the learning/working memory composite indicated that
the cut score that had optimal sensitivity and specificity
in classifying cognitive impairment in MCI was 90 (i.e.,
z < = −1 SD). Application of this same cut score to clas-
sification of cognitive impairment in AD yielded a sensi-
tivity of 100% at the same specificity (Table 2).










Psychomotor/attention AD 52.9% (38.5%, 67.1%) 85.7% (82.8%, 88.3%) 0.73 (0.64, 0.82) 0.05 < 0.0001
MCI 41.1% (31.7%, 51.1%) 85.7% (82.8%, 88.3%) 0.67 (0.61, 0.73) 0.03 < 0.0001
Score < 90 Score < 90
Learning/working memory AD 100.0% (91.5%, 100.0%) 84.7% (81.7%, 87.4%) 0.99 (0.98, 1.00) 0.01 < 0.0001
MCI 80.4% (71.6%, 87.4%) 84.7% (81.7%, 87.4%) 0.91 (0.87, 0.94) 0.02 < 0.0001
Note: ROC = receiver operating characteristic; MCI = mild cognitive impairment; AD = Alzheimer’s disease; Attention/psychomotor composite = average of the
standardized Detection and Identification scores; Learning/working memory composite = average of the standardized One Card Learning and One Back scores;
MMSE =Mini Mental State Examination.
Maruff et al. BMC Pharmacology and Toxicology 2013, 1:30 Page 6 of 11
http://www.biomedcentral.com/2050-7283/1/30Prediction of MCI and AD from combined composite
scores
Table 3 shows the odds ratios for classification of MCI
or AD (versus HA) for the combination of cognitive
impairment of a score ≤90 on the learning/working
memory composite and >/=90 on the attention/psycho-
motor composite. This analysis showed that with these
cut scores, individuals were 26 times more likely to meet
clinical criteria for MCI, and 30 times more likely to
meet clinical criteria for AD.
Relationship to disease severity
For the relationship between MMSE scores and the at-
tention/psychomotor composite, trend analysis indicated
no statistically significant relationships in any clinicalFigure 1 ROC curve for performance of the MCI group (a) and the AD
memory composite and the attention/psychomotor composite.group. The relationship between MMSE scores and the
learning/working memory composite was best described
by a linear function in both the MCI (r = 0.38) and AD
(r = 0.12) groups, although this relationship was statisti-
cally significant only for the MCI group.
For the relationship between CDR sum of boxes scores
and the attention/psychomotor composite, trend analysis
indicated that when both MCI and AD groups were
collapsed, there was a statistically significant linear rela-
tionship between increasing disease severity and worse
performance on the attention/psychomotor composite
(Figure 2a). Similarly, statistically significant linear rela-
tionships were observed between CDR sum of boxes
scores and the learning/working memory composite when
both the MCI and AD groups were collapsed (Figure 2b).group (b) relative to the HC group on the learning/working








Healthy controls (HC) 480 84
Mild cognitive impairment (MCI) 12 55 HC vs. MCI 26.19 (13.45, 50.98) < 0.0001
Alzheimer’s disease (AD) 4 21 HC vs. AD 30.00 (10.05, 89.60) <0.0001
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The ICC for both composites are shown in Table 4.
When considered according to clinical classification,
both composites demonstrated high (i.e., r > 0.70) test-
retest reliability over a four month assessment period
and these estimates were equivalent between the clinical
groups (see Table 4).
Discussion
Results of this study supported our first hypothesis that
the learning/working memory composite and the atten-
tion/psychomotor composite, derived from the outcome
measures on the CBB, would be sensitive to detecting cog-
nitive impairment in MCI and AD. In AD, we observed a
large impairment for both cognitive composite scores, al-
though the magnitude of impairment on the learning/
working memory composite was much greater than that
for the attention/psychomotor composite. Neuropsycho-
logical models of the cognitive tasks that contribute to the
learning/working memory composite suggest that normal
performance on these tasks is likely to depend on the in-
tegrity of the hippocampus and temporal lobe (i.e. patterna b
Figure 2 Relationship between performance on the CDR Sum of Boxe
working memory composite (b) in individuals with MCI and AD. The d
for each group of individuals with the same score on the CDR-SOB.separation, e.g., Yassa et al. 2010) and prefrontal cortex
and anterior cingulate (i.e. working memory, Andrewes
2001; Lezak 1995). Normal performance on the tasks that
contribute to attentional functions are likely to depend on
integrity of subcortical brain regions including the basal
ganglia as well as cortical regions such as the prefrontal
and parietal cortices (Andrewes 2001; Lezak 1995). The
presence of a relatively greater impairment in cognitive
functions dependent on cortical and limbic brain regions
(i.e., learning and working memory) with relatively sub-
tle impairment in motor and attentional functions is
consistent with neuropsychological models of AD which
emphasise that cognitive impairment characteristic of
both prodromal and clinically classified AD is disrup-
tion to memory and executive function (Baddeley et al.
1991; Kensinger et al. 2003; McKhann et al. 2011). This
pattern of impairment is also consistent with the predi-
lection of AD-related neuronal loss in the medial tem-
poral lobe and other cortical brain areas (Jack et al.
2009; Villemagne et al. 2013).
Differences in the nature of impairment for the two
cognitive composite scores were also evident in theirs and the attention/psychomotor composite (a) and the learning/
iamond markers on each figure represent the mean composite score
Table 4 Test-retest reliability and group mean (standard deviation) of each clinical group over a four month
assessment period
Month 1 Month 2 Month 3 Month 4
Composite ICC (95% CI) p Mean SD Mean SD Mean SD Mean SD
Overall Attention 0.90 (0.87, 0.92) <.0001 96.46 11.97 95.79 15.65 95.66 11.79 97.37 23.16
Memory 0.95 (0.93, 0.96) <.0001 93.03 14.09 94.16 13.3 95.17 14.6 96.39 14.76
HC Attention 0.94 (0.92, 0.96) <.0001 100 8.86 98.86 9.08 99.26 8.81 101.27 27.59
Memory 0.78 (0.70, 0.85) <.0001 99.92 8.05 100.73 8.37 102.61 8.86 104.57 7.39
MCI Attention 0.94 (0.90, 0.97) <.0001 95.69 11.73 93.66 11.6 93.9 12.53 95.42 11.33
Memory 0.86 (0.78, 0.92) <.0001 92.18 10.99 92.16 9.51 92.53 11.03 93.89 10.02
AD Attention 0.77 (0.58, 0.89) <.0001 86.76 14.83 88.96 28.53 86.56 13.8 88.04 14.65
Memory 0.91 (0.84, 0.96) <.0001 73.4 13.07 75.95 12.26 75.1 13.11 75.16 13.46
Note: ICC = Intra-class correlation coefficient; HC = healthy controls; MCI =mild cognitive impairment; AD = Alzheimer’s disease; Attention/psychomotor composite =
average of the standardized Detection and Identification scores; Learning/working memory composite = average of the standardized One Card Learning and One
Back scores.
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in individuals. The learning/working memory composite
was most sensitive to AD-related cognitive impairment
with 100% of AD cases classified as impaired when the
criterion for abnormality was set at a score of 90. When
the criterion for abnormality was decreased to 80, the sen-
sitivity for abnormality decreased to only 86% (Figure 1).
As expected, the attention/psychomotor composite showed
lower levels of sensitivity, with only 53% of AD cases iden-
tified when sensitivity was set at the least conservative level
(i.e., score of 90). Taken together, these data indicate that
with the use of these composite scores, cognitive impair-
ment in AD will present as a relatively large impairment in
working memory and learning and with relatively intact
psychomotor and attentional functions. The nature and
magnitude of this cognitive impairment is consistent with
the descriptions of AD cases from the neuropsychological
literature (Andrewes 2001; McKhann et al. 2011). While it
is unsurprising that patients with clinical defined AD
showed poor performance on a measure of learning and
working memory, the high specificity of the learning/work-
ing memory composite, with the lesser impairment on the
attention/psychomotor composite also indicates that the
CogState tests themselves can be used effectively in pa-
tients with AD and suggests further that this pattern of
performance may even be useful to clinicians investigating
the aetiology of cognitive impairment in older adults.
As expected, in adults with MCI, cognitive impairment
was qualitatively similar but quantitatively less pronounced
to that observed for clinically diagnosed AD. Compared to
healthy adults, the MCI group showed large impairment
on the learning/working memory composite (g = 2.2),
although not as great as that observed for the same com-
posite in AD. While performance on the attention/psycho-
motor composite was also impaired compared to healthy
adults, the magnitude of this impairment was only moder-
ate (g = 0.51). Once again this impairment was less thanthat observed for the same composite in AD. Despite these
impairment, performance on both the attention/psycho-
motor function and learning working memory composites
in the MCI group was superior to that in the AD group.
When considered for individuals, a score of ≤90 on the
learning/working memory composite had optimal sensitiv-
ity and specificity for detecting cognitive impairment in
MCI. At the optimum cut score for the attention/psycho-
motor composite, the sensitivity was only 40%, with a
specificity of 85%. Therefore, as was observed for AD, cog-
nitive impairment in MCI was characterised best as a large
abnormality in working memory and learning with rela-
tively normal psychomotor and attentional function. The
likelihood that a combination of abnormal performance on
the learning/working memory composite with normal per-
formance on the attention/psychomotor composite could
predict MCI or AD was very high, since individuals who
met this criteria were 26 times more likely to have MCI or
30 times more likely to have AD than those who did not
meet the criteria.
For the relationship between cognition and disease se-
verity in the MCI and AD groups, while a significant lin-
ear relationship was observed between disease severity
and the attention/psychomotor composite, this relation-
ship was driven mainly by individuals with the most
extreme scores on the severity measure. Furthermore
the magnitude of this relationship was only small. In
contrast to these more reflexive aspects of cognition,
disease severity was strongly associated with the learn-
ing/working memory composite.
The second hypothesis that the attention/psychomotor
composite and the learning/working memory composite
would show high test-retest reliability and stability in
healthy adults, adults with MCI and AD, was also sup-
ported. Assessments on the same tests conducted four
times in three months showed that both composite
scores remained stable and showed test-retest reliability
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testing over relatively short retest intervals, including in
patients with cognitive impairment, both composites
showed no evidence of practice effects, and estimates of
within subject variability remained low. Further, esti-
mates of test-retest reliability for each composite were,
by convention, high (r > 0.70). These results are consist-
ent with findings from earlier clinical studies of MCI
and AD groups, which have shown that performance on
the individual tests from the CBB show little to no prac-
tice effects, have high test-retest reliability, and have low
within-subject variability (Darby et al. 2012; Fredrickson
et al. 2010; Lim et al. 2013b). While individual measures
from the CogState battery have been shown to be sensitive
to cognitive decline in MCI (e.g. Lim et al. 2012a, b), it will
be important now to determine the extent to which com-
posite scores derived in this study will be also sensitive to
cognitive decline in MCI.
Taken together, results of this study converge to suggest
that the performance on the learning/working memory
and attention/psychomotor composites of the CBB can be
used to identify reliably cognitive impairment in people
with, and at risk of AD. Thus the two composite scores
from the CBB should be useful in screening for cognitive
impairment in MCI or AD. The estimates of sensitivity for
the composite scores from the CBB reported here are
equivalent or slightly better than those reported previously
for other screening instruments used commonly in the
early identification of aMCI and AD. For example, esti-
mates of the sensitivity for the MoCA show that the total
score has a high sensitivity to AD, while retaining a high
specificity. However, as was observed in the current study,
the sensitivity of the MoCA to aMCI is also relatively high
(81%; (Freitas et al. 2013)), provided that estimates of
lower levels of specificity (e.g. 77%) are tolerated. As with
the MoCA, performance on the MMSE also shows rela-
tively high sensitivity and specificity for identifying cogni-
tive impairment in AD (Freitas et al. 2013; Strauss et al.
2006) although its sensitivity to cognitive impairment in
MCI is lower than the MoCA and that reported here, even
if a low specificity is allowed. The equivalence of these es-
timates occurs mainly because all studies use the same
method, where the test instrument is applied to identify
cognitive impairment in a group of individuals that has
been carefully assessed and undergone relatively rigorous
inclusion and exclusion criteria. One strength of the com-
posite scores, observed in this study, was that they were
not associated with estimates of premorbid intelligence or
depressive symptoms. The psychomotor attention com-
posite was associated with levels of anxiety symptoms al-
though the magnitude of this association was very small.
Taken together this analysis of associations suggests that
the composite cognitive scores may be useful in settings
where issues such as low premorbid intelligence or moodobscure the assessment of cognitive function in individ-
uals undergoing clinical workup for MCI or AD.
When cognitive assessments are conducted in unse-
lected populations, such as in epidemiological studies,
neuropsychological tests are always preferred to bedside
screening instruments for the identification of cognitive
impairment (Clarke et al. 2000; Ellis et al. 2009; Petersen
et al. 2010). This is because neuropsychological tests
provide more reliable estimates of individual cognitive
functions. Acceptable estimates of validity and reliability
are found for bedside screening instruments only when
their total score is used, and accordingly, scores of their
subscales have been shown to have limited use for describ-
ing the nature of cognitive impairment in individuals
(Strauss et al. 2006). A limitation of bedside screening in-
struments for tracking cognitive function is reflected in
their absence as outcome measures in clinical trials of
drugs designed to improve cognitive function in MCI or
AD. This is due to restriction in the range of possible
scores for people with dementia; the presence of ceiling ef-
fects in data distributions; and the substantial practice ef-
fects that occur with repeated administrations. As with
other neuropsychological tests, the tasks from the CBB
have been used extensively in epidemiological studies, as
well as in clinical trials (Bateman et al. 2011; Ellis et al.
2009). Furthermore associations between performance on
the CBB tasks and that on conventional neuropsycho-
logical measures indicate that each task has sound con-
struct validity (Maruff et al. 2009). The data shown here
extend these findings to suggest that the two cognitive
composite scores that arise from individual measures that
comprise the CBB could be applied effectively as a cogni-
tive screening instrument not only for assessing cognitive
impairment in dementia, but also in other neurological
and psychiatric conditions.
There are some limitations in the current study that war-
rant consideration in interpreting the results. First, as has
been considered already the current data for this study
were drawn from studies of MCI and AD, therefore the
high sensitivity and specificity demonstrated here should
be challenged in individuals from a clinical setting. Second,
while the MCI group recruited here met clinical criteria
shown to increase the risk of AD (Petersen et al. 1999),
amyloid biomarkers (e.g., Petersen et al. 2010) were not
measured in the current analysis. Therefore, although the
current data show that the learning/working memory com-
posite score was sensitive to the cognitive impairment that
characterizes MCI more study is needed to determine the
relationship the relationship between the CogState com-
posite scores and amyloid biomarkers within this clinical
classification. These issues notwithstanding the current re-
sults do show that the composite scores from the CogState
Brief Battery have good potential for use in screening for
cognitive impairment related to MCI and AD.
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